Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now?

Is HRMY a bully banal to buy? We came crossed a bullish thesis on Harmony Biosciences Holdings, Inc. connected r/StockPickNews by EaseQuiet529. In this article, we volition summarize the bulls' thesis connected HRMY. Harmony Biosciences Holdings, Inc.'s stock was trading astatine $34.10 arsenic of June 9th. HRMY's trailing and guardant P/E were 13.75 and 10.81 respectively according to Yahoo Finance.

Pressmaster/Shutterstock.com

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses connected processing and commercializing therapies for patients with uncommon neurological diseases successful the United States. HRMY is emerging arsenic a compelling accidental successful the biopharma abstraction pursuing a play of marketplace underappreciation, with its existent valuation failing to bespeak the spot of its halfway plus and maturation pipeline.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Trading astir $27.70–$27.80 with a humble marketplace capitalization of astir $1.6 billion, the banal appears importantly discounted comparative to its fundamentals, arsenic evidenced by a debased trailing P/E of ~7.8x and guardant P/E of ~11.4x, alongside a PEG ratio of conscionable 0.38.

The company's flagship drug, WAKIX, remains the cornerstone of its concern thesis, with absorption reaffirming 2026 gross guidance of $1.0 cardinal to $1.04 billion, positioning the cause to execute blockbuster status. This milestone not lone reinforces the durability of its gross basal but besides highlights the scalability of its commercialized platform. Harmony Biosciences benefits from beardown portion economics, including a robust 77% gross margin, and operates arsenic a self-funded entity, reducing reliance connected outer superior and limiting shareholder dilution.

Beyond WAKIX, the pipeline provides further upside, with a New Drug Application for Pitolisant GR expected successful Q2 2026 and a Phase 3 topline information readout anticipated successful the 2nd fractional of the year, some serving arsenic meaningful catalysts. With expert terms targets ranging from $42 to $47, implying astir 50–60% upside, the banal offers an charismatic risk-reward illustration supported by net growth, pipeline optionality, and operational strength, making it a high-conviction bullish opportunity.

Previously, we covered a bullish thesis connected CRISPR Therapeutics AG (CRSP) by MADD-Scientis successful March 2025, which highlighted the imaginable of Casgevy arsenic a blockbuster gene-editing therapy, beardown nett currency position, and a robust pipeline driving important upside. CRSP's banal terms has appreciated by astir 25.65% since our coverage. EaseQuiet529 shares a akin presumption but emphasizes connected Harmony Biosciences' undervaluation, beardown WAKIX gross visibility, and near-term pipeline catalysts.